Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in FARN?
Faron Pharmaceuticals Ltd: THE INVESTMENT CASE

Faron Pharma boss “excited” to begin first in-human trial of Clevegen later this year

A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
immunotherapy graphic
Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system

Faron Pharmaceuticals Ltd (LON:FARN) boss Markku Jalkanen has told investors he is “excited” to kick off the first in-human trial of his firm’s Clevegen cancer candidate later this year.

Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system.

READ: Faron welcomes latest Clever-1 data

The technology focuses on Clever-1, a surface cell receptor involved in cancer growth and spread. The changes anti-Clever-1 antibodies such as Clevegen induce allow immune cells to attack and kill cancer cells.

“We have continued to make good progress with our Clevegen programme and are very excited to start the first human clinical trial later this year,” said Markku Jalkanen.

“Our focus for the remainder of 2018 will be to continue to rapidly progress Clevegen through the clinic whilst also continuing to preserve cash in order to deliver value to shareholders.”

The focus on oncology followed disappointing Phase III top-line data from its lead drug, Traumakine for the condition called acute respiratory distress.

READ: Here's how Clevegen works 

Faron is still analysing the full dataset from that trial, while further data from separate studies are due over the coming months.

“Whilst we were disappointed with the results from the INTEREST study, we have made, and are continuing to make, efforts to fully understand the data in order to define the next steps in the Company's strategy for Traumakine,” added Jalkanen.

“The company will closely collaborate with the clinical community to complete this analysis and plan to provide full analysis of these findings in October.”

Plenty of cash

AIM-listed Faron had €11.2mln in the bank at the end of June (H1 17: €10.3mln), having raised just shy of €16mln in February.

It recorded an operating loss of €14.0mln for the opening six months of 2018 (H1 17: €6.8mln), although it has put in place a plan to help it reduce its cash burn going forward.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

September 12 2018

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use